Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 16/20 | 0.58 |
| ▸ | P2RX2 | Q9UBL9 | 16/20 | 0.58 |
| ▸ | DHFR | P00374 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29839589 | 1.00 | P2RX3 (0.58) | P2RX3P2RX2DHFR | |
| SCHEMBL29839486 | 0.83 | P2RX3 (0.69) | P2RX3P2RX2DHFR | |
| SCHEMBL22439351 | 0.83 | P2RX3 (0.69) | P2RX3P2RX2DHFR | |
| SCHEMBL1493932 | 0.82 | P2RX3 (0.72) | P2RX3P2RX2DHFR | |
| SCHEMBL30215892 | 0.82 | P2RX3 (0.72) | P2RX3P2RX2DHFR | |
| SCHEMBL1494346 | 0.82 | P2RX3 (0.67) | P2RX3P2RX2DHFR | |
| SCHEMBL30215744 | 0.82 | P2RX3 (0.67) | P2RX3P2RX2DHFR | |
| SCHEMBL22439629 | 0.77 | P2RX3 (0.72) | P2RX3P2RX2 | |
| SCHEMBL30625063 | 0.77 | P2RX3 (0.72) | P2RX3P2RX2 | |
| SCHEMBL22439407 | 0.76 | P2RX3 (0.67) | P2RX3P2RX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3712144-B1 | P2X3 AND/OR P2X2/3 RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO LTD (CN) | 2024-02-14 | — | — | EP | disclosed |
| US-20220389039-A1 | P2X3 AND/OR P2X2/3 RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO LTD (CN) | 2022-12-08 | — | — | US | disclosed |
| US-20220211703-A1 | METHOD FOR TREATING COUGH BY USING DIAMINOPYRIMIDINE COMPOUND | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2022-07-07 | — | — | US | disclosed |
| US-20210179648-A1 | P2X3 AND/OR P2X2/3 RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2021-06-17 | — | — | US | disclosed |
| US-20210179648-A1 | P2X3 AND/OR P2X2/3 RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2021-06-17 | — | — | US | disclosed |
| EP-3712144-A1 | P2X3 AND/OR P2X2/3 RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | Beijing Tide Pharmaceutical Co., Ltd. (CN) | 2020-09-23 | — | — | EP | disclosed |
| EP-3712144-A1 | P2X3 AND/OR P2X2/3 RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | Beijing Tide Pharmaceutical Co., Ltd. (CN) | 2020-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210179648-A1 | P2X3 AND/OR P2X2/3 RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | P2RX3, P2RX2, P2RX7 | P2RX3 1/4885P2RX2 2/4885DHFR 2884/4885 |
| US-20220389039-A1 | P2X3 AND/OR P2X2/3 RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | P2RX3, P2RX2, P2RX7 | P2RX3 1/4885P2RX2 2/4885DHFR 3038/4885 |
| US-20220211703-A1 | METHOD FOR TREATING COUGH BY USING DIAMINOPYRIMIDINE COMPOUND | NUDT1, DPYD, PEPD | P2RX3 276/4885P2RX2 282/4885DHFR 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.